Demand for Guerbet's contrast agent soars

By staff writers

November 30, 2021 -- Contrast developer Guerbet has reported a strong rise in demand for its Dotarem (gadoterate meglumine) injection due to the pandemic and supply chain disruptions.

The company said it shipped more doses of the gadolinium-based MRI contrast agent in October than in any other monthly period since its U.S. release in 2013. Guerbet has delivered more than 120 million doses in 70 countries, it noted.

Copyright © 2021

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking